knowledge -WSS

knowledge

author：fashion 2025-09-06 04:40:51 - browse：2

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Cytokinetics CEO stresses company can launch heart drug on its own

WSS

With measles on the rise, a personal story of a devastating disease

General Catalyst, Summa Health deal will turn on physician buy

Vertigo drug brings hope for rare neuron disorder, Niemann

The real point of Kenneth Smith’s execution by nitrogen gas

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Medicare drug price negotiation’s day in court

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Bright Health sells Medicare Advantage business to Molina

Solving academic medical centers' existential crisis

DIEP, the 'gold standard' of breast reconstruction, is under threat

Apple Vision Pro: A first look at health apps on the new VR headset

Peter Hotez and the public health issue of online harassment

Readout LOUD podcast: Live from STAT Breakthrough Summit West

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Addiction experts warn against a second 'war on drugs'

Psychedelics group wrestles with new pharma identity

Some dementia cases could be undiagnosed liver disease

hotspot

Case highlights the risks of experimental stem cell therapy

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

General Catalyst, Summa Health deal will turn on physician buy

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Covid misinformation case heads to Supreme Court

leisure time

explore

hotspot

hotspot